Search hospitals > Nevada > Las Vegas

Las Vegas Cancer Center-Medical Center

Claim this profile
Las Vegas, Nevada 89106
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Ovarian Cancer
Conducts research for Adenocarcinoma
Conducts research for Fallopian Tube Cancer
253 reported clinical trials
5 medical researchers
Photo of Las Vegas Cancer Center-Medical Center in Las VegasPhoto of Las Vegas Cancer Center-Medical Center in Las VegasPhoto of Las Vegas Cancer Center-Medical Center in Las Vegas

Summary

Las Vegas Cancer Center-Medical Center is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Recurrence, Ovarian Cancer, Adenocarcinoma, Fallopian Tube Cancer and other specialties. Las Vegas Cancer Center-Medical Center is involved with conducting 253 clinical trials across 419 conditions. There are 5 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, Nicola M. Spirtos, and Peter Lim.

Area of expertise

1Cancer
Global Leader
Las Vegas Cancer Center-Medical Center has run 115 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Recurrence
Global Leader
Las Vegas Cancer Center-Medical Center has run 52 trials for Recurrence. Some of their research focus areas include:
Stage IV
Stage III
Stage I

Top PIs

Clinical Trials running at Las Vegas Cancer Center-Medical Center

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Bladder Cancer
Bladder Carcinoma
Gastric Cancer
Renal Cell Carcinoma
Endometrial Cancer
Esophageal Cancer
Image of trial facility.

Symptom Monitoring

for Young Women on Hormone Therapy

This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
Image of trial facility.

Marker-Directed Monitoring

for Breast Cancer

This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Las Vegas Cancer Center-Medical Center?
Las Vegas Cancer Center-Medical Center is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Recurrence, Ovarian Cancer, Adenocarcinoma, Fallopian Tube Cancer and other specialties. Las Vegas Cancer Center-Medical Center is involved with conducting 253 clinical trials across 419 conditions. There are 5 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, Nicola M. Spirtos, and Peter Lim.